KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Vir Biotechnology (VIR) Income towards Parent Company (2018 - 2025)

Vir Biotechnology's Income towards Parent Company history spans 8 years, with the latest figure at -$42.9 million for Q4 2025.

  • On a quarterly basis, Income towards Parent Company rose 58.96% to -$42.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$438.0 million, a 16.09% increase, with the full-year FY2025 number at -$438.0 million, up 16.09% from a year prior.
  • Income towards Parent Company hit -$42.9 million in Q4 2025 for Vir Biotechnology, up from -$163.1 million in the prior quarter.
  • Over the last five years, Income towards Parent Company for VIR hit a ceiling of $525.3 million in Q4 2021 and a floor of -$213.7 million in Q3 2024.
  • Historically, Income towards Parent Company has averaged -$26.5 million across 5 years, with a median of -$107.8 million in 2024.
  • Biggest five-year swings in Income towards Parent Company: surged 597.17% in 2021 and later tumbled 223.75% in 2022.
  • Tracing VIR's Income towards Parent Company over 5 years: stood at $525.3 million in 2021, then plummeted by 119.34% to -$101.6 million in 2022, then fell by 14.14% to -$116.0 million in 2023, then rose by 9.82% to -$104.6 million in 2024, then skyrocketed by 58.96% to -$42.9 million in 2025.
  • Business Quant data shows Income towards Parent Company for VIR at -$42.9 million in Q4 2025, -$163.1 million in Q3 2025, and -$111.0 million in Q2 2025.